Elutia Inc

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Elutia Inc reports solid Q1 performance, eyes market disruption

Elutia Inc's Q1 2024 showcased strong revenue growth and operational improvements, with a focus on product line expansions and margin enhancement.
While facing challenges in gross margin decline and expense management, the company is strategically positioned to capitalize on market disruptions and growth opportunities.
By leveraging FDA clearances, product line strengths, and cost-saving initiatives, Elutia Inc aims to drive profitability and sustainable growth in the competitive healthcare market.

Elutia Inc reports stable Q2 performance and positions EluPro for market leadership

Elutia Inc's Q2 performance reflects stability and growth, supported by operational efficiency and strategic financial management.
The company's focus on EluPro's commercialization, expansion efforts, and market positioning underscores a commitment to innovation and market leadership.
While facing challenges in pricing and sales expansion, Elutia is well-positioned to capitalize on opportunities in diverse medical markets and drive long-term growth.

Elutia Inc reports positive Q3 earnings amidst operational challenges

Elutia Inc's Q3 performance showed positive net income but an EBITDA loss, with $5.9 million in sales.
Strengths include EluPro approval, expanding commercial footprint, and positive net income.
Challenges include EBITDA loss, rising operating expenses, and transitioning to EluPro.
Opportunities lie in SimpliDerm sales growth, market adoption of EluPro, and strategic investments.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Elutia, Inc. operates as a biotechnology company. It develops biologic products to improve compatibility between medical devices and the patients who need them. The firm operates through the following segments: Device Protection, Women’s Health, Orthobiologics and Cardiovascular. The Device Protection segment includes biological envelope that remodels into systematically connected, vascularized tissue for the long-term pocket protection of certain cardiac and neurostimulator implantable electronic vehicles. The Women’s Health segment includes pre-hydrated, human acellular dermal matrix, or HADM, that is designed to enable rapid integration, cellular repopulation and rapid revascularization at the surgical site. The Orthobiologics segment includes a variety of viable matrices, produced with a proprietary process that is designed to protect and preserve native bone cells and reduce programmable cell death, for use in bone repair and fusion procedures. The Cardiovascular segment includes a portfolio of extracellular matrices that retain the natural composition of collagen, growth factors and proteins for use in vascular and cardiac repair and pericardial closure. The company was founded by Kevin L. Rakin and Charles Randal Mills on August 6, 2015 and is headquartered in Silver Spring, MD.

Here is how Elutia Inc. (ELUT) and Adma Biologics (ADMA) have performed compared to their sector so far this year.

Are Medical Stocks Lagging ELUTIA INC (ELUT) This Year?

Elutia Inc. (NASDAQ:ELUT ) Q3 2024 Earnings Conference Call November 14, 2024 4:30 PM ET Company Participants Matt Steinberg – FINN Partners Randy Mills – Chief Executive Officer Matt Ferguson – Chief Financial Officer Conference Call Participants Frank Takkinen – Lake Street Capital Markets Ross Osborn – Cantor Fitzgerald Operator Greetings. Welcome to the Elutia Third Quarter 2024 Financial Results Call.

Elutia Inc. (ELUT) Q3 2024 Earnings Call Transcript

SILVER SPRING, Md., Oct. 23, 2024 (GLOBE NEWSWIRE) -- Elutia Inc. (Nasdaq: ELUT) (“Elutia”), a leader in drug-eluting biomatrix products, today announced that Dr. Randy Mills, President and Chief Executive Officer, will present at the LD Micro Main Event XVII Conference in Los Angeles on Wednesday, October 30, 2024, at 2:00 p.m. PT (5:00 p.m. ET).

Elutia to Present at the LD Micro Main Event XVII Conference on Wednesday, October 30

EluPro eradicated bacteria commonly associated with cardiac implant-related infections in an established preclinical infection model

Elutia Announces New Peer Reviewed Publication Highlighting the Robustness of EluPro™, Company's Antibiotic-Eluting BioEnvelope for Implantable Devices

Company Thanks Stakeholders and Employees for a Year of Remarkable Growth and Accomplishment SILVER SPRING, Md., Sept. 06, 2024 (GLOBE NEWSWIRE) -- Elutia Inc. (Nasdaq: ELUT) (“Elutia”), a pioneer in drug-eluting biomatrix products, is celebrating its one-year anniversary and the team that made it possible.

Elutia Celebrates First Year

SILVER SPRING, Md., Sept. 05, 2024 (GLOBE NEWSWIRE) -- Elutia Inc. (Nasdaq: ELUT) (“Elutia”), a pioneer in drug-eluting biomatrix products, today announced a landmark achievement with the first-ever patient implant of EluPro®, the world's first antibiotic-eluting biologic envelope cleared by the U.S. Food and Drug Administration (FDA). The groundbreaking procedure was performed by John Catanzaro, MD, MBA, Chief, Division of Cardiology, Director, Cardiology Services, and Program Director of Clinical Cardiac Electrophysiology Fellowship at East Carolina University Health Medical Center in Greenville, North Carolina.

Elutia Announces First Patient Implant of EluPro™, the World's First Drug-Eluting BioEnvelope for Cardiac Pacemakers and Neurostimulators

SILVER SPRING, Md., Sept. 03, 2024 (GLOBE NEWSWIRE) -- Elutia Inc. (Nasdaq: ELUT) (“Elutia”), a pioneer in drug-eluting biomatrix products, today announced that Dr. Randy Mills, President and Chief Executive Officer, and Matt Ferguson, Chief Financial Officer, will participate in the following upcoming investor conferences in New York:

Elutia to Participate in Upcoming Investor Conferences

Citizens

Cadrenal Therapeutics Inc

Euda Health Holdings Ltd

Cytomed Therapeutics Ltd

Gossamer Bio Inc

Geovax Labs

Immuron

Intelligent Bio Solutions Inc

iQSTEL Inc.

Prospector LeddarTech Almalco

Nature's Miracle California Inc

Pure Cycle

Peraso

SunCar Technology Group Inc

22nd Century Group

MIAMI, Aug. 20, 2024 (GLOBE NEWSWIRE) -- EmergingGrowth.com a leading independent small cap media portal announces the schedule of the 74th Emerging Growth Conference on August 21 – 22, 2024.

Presenting on the Emerging Growth Conference 74 Day 1 on August 21 Register Now

Elutia Inc. (NASDAQ:ELUT ) Q2 2024 Earnings Conference Call August 7, 2024 4:30 PM ET Company Participants Matt Steinberg - Finn Partners, IR Randy Mills - President and CEO Matt Ferguson - Chief Financial Officer Conference Call Participants Matthew Park - Cantor Fitzgerald Frank Takkinen - Lake Street Capital Markets Operator Greetings. Welcome to the Elutia Second Quarter 2024 Financial Results Call.

Elutia Inc. (ELUT) Q2 2024 Earnings Call Transcript

SILVER SPRING, Md., July 31, 2024 (GLOBE NEWSWIRE) -- Elutia Inc. (Nasdaq: ELUT) (“Elutia”), a pioneer in drug-eluting biomatrix products, today announced the appointment of Ryan Marques, Ph.D, MBA as Vice President of Operations. Dr. Marques brings more than 20 years of experience leading operations teams across manufacturing, quality assurance, supply chain and technical services in the device and pharmaceutical industries.

Elutia Appoints Ryan Marques, Ph.D., MBA as Vice President of Operations

SILVER SPRING, Md., July 11, 2024 (GLOBE NEWSWIRE) -- Elutia Inc. (Nasdaq: ELUT) (“Elutia”), a pioneer in drug-eluting biomatrix products, today announced that Dr. Randy Mills, President and Chief Executive Officer, will present at the Emerging Growth Conference on Thursday, July 18, 2024, at 12:35 p.m. ET (9:35 a.m. PT).

Elutia to Present at the Emerging Growth Conference on Thursday, July 18

Archer Aviation

ADC Therapeutics

Grab Holdings Ltd

National CineMedia

PaySign Inc

With growth stocks under $5, the focal point is rather obvious: putting woodwork on the ball as aggressively as possible. Of course, swinging for the fences comes with significant risks.

7 Growth Stocks to Buy for Under $5 for Massive Gains

Black Rifle Coffee

Costamare

BRC (BRCC), Costamare (CMRE) and Elutia (ELUT) have been selected as the breakout stocks for today.

3 Best Breakout Stocks Worth a Buy for Attractive Returns

SILVER SPRING, Md., June 17, 2024 (GLOBE NEWSWIRE) -- Elutia Inc. (Nasdaq: ELUT) (“Elutia” or the “Company”) today announced it has entered into a definitive agreement with investors for the purchase and sale of 3,175,000 shares of the Company's Class A common stock at a purchase price of $3.40 per share and 725,000 prefunded warrants to purchase up to 725,000 shares of the Company's Class A common stock at a purchase price of $3.399 per prefunded warrant in a registered direct offering. The prefunded warrants are immediately exercisable at an exercise price of $0.001 per each prefunded warrant. The gross proceeds to Elutia from the offering are expected to be approximately $13.26 million, before deducting placement agent fees and other offering expenses payable by Elutia. The offering is expected to close on or about June 18, 2024, subject to customary closing conditions.

Elutia Announces $13.26 Million Registered Direct Offering

EluPro becomes the only drug-eluting biologic envelope to receive FDA clearance in the $600 million U.S. implantable electronic device protection market

Elutia Announces FDA Clearance of EluPro®: The First Antibiotic-Eluting BioEnvelope Designed to Protect Patients with Implantable Cardiac Pacemakers and Defibrillators

Elutia, Inc. (NASDAQ:ELUT ) Q1 2024 Earnings Conference Call May 9, 2024 4:30 PM ET Company Participants Matt Steinberg - Finn Partners Randy Mills - President and Chief Executive Officer Matthew Ferguson - Chief Financial Officer Conference Call Participants Frank Takkinen - Lake Street Capital Markets Matthew Lambert - Cantor Fitzgerald Operator Good afternoon, ladies and gentlemen. Welcome to the Elutia First Quarter 2024 Financial Results Conference Call.

Elutia, Inc. (ELUT) Q1 2024 Earnings Call Transcript

SILVER SPRING, Md., April 24, 2024 (GLOBE NEWSWIRE) -- Elutia Inc. (Nasdaq: ELUT) (“Elutia”), a company pioneering drug-eluting biomatrix products, today announced that Dr. Randy Mills, President and Chief Executive Officer, and Matt Ferguson, Chief Financial Officer, will present at the Planet MicroCap Showcase: VEGAS 2024 on Wednesday, May 1, 2024, at 3:00 p.m. ET (12:00 p.m. PT).

Elutia to Present at the Planet MicroCap Showcase: VEGAS 2024 on Wednesday, May 1

Elutia, Inc. (NASDAQ:ELUT ) Q4 2023 Results Conference Call March 7, 2024 4:30 PM ET Company Participants Matt Steinberg - Finn Partners Randy Mills - President and Chief Executive Officer Matt Ferguson - Chief Financial Officer Conference Call Participants Frank Takkinen - Lake Street Capital Markets Ross Osborn - Cantor Fitzgerald Operator Greetings. Welcome to the Elutia Fourth Quarter and Full-Year 2023 Financial Results Call.

Elutia, Inc. (ELUT) Q4 2023 Earnings Call Transcript

SILVER SPRING, Md., March 07, 2024 (GLOBE NEWSWIRE) -- Elutia Inc. (Nasdaq: ELUT) (“Elutia” or the “Company”) today provided a business update and reported financial results for the fourth quarter and full year ended December 31, 2023.

Elutia Reports Fourth Quarter and Full Year 2023 Financial Results: Anticipates CanGarooRM® Clearance Decision in First Half of 2024

SILVER SPRING, Md., Feb. 22, 2024 (GLOBE NEWSWIRE) -- Elutia Inc. (Nasdaq: ELUT) (“Elutia”), a company pioneering drug-eluting biomatrix products, today announced that it will release its fourth quarter and full year 2023 financial results after market close on Thursday, March 7, 2024. Members of the Company's management team will host a conference call and webcast starting at 4:30 p.m. Eastern Time / 1:30 p.m. Pacific Time on the same day.

Elutia to Report Fourth Quarter and Full Year 2023 Financial Results on Thursday, March 7, 2024

SILVER SPRING, Md., Jan. 10, 2024 (GLOBE NEWSWIRE) -- Elutia Inc. (Nasdaq: ELUT) today announced that it has regained compliance with Nasdaq's market value of listed securities requirement and majority independent board requirement. As a result, the Company now satisfies all applicable requirements for continued listing with Nasdaq, and the Company's Class A common stock will continue to be listed and traded on the Nasdaq Capital Market under the symbol “ELUT.”

Elutia Regains Compliance with Nasdaq Listing Requirements

Elutia Inc. (ELUT) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

Elutia Inc. (ELUT) Upgraded to Buy: Here's Why

Elutia, Inc. (NASDAQ:ELUT ) Q3 2023 Results Conference Call November 13, 2023 4:30 PM ET Company Participants David Carey - Finn Partners Randy Mills - President and Chief Executive Officer Matt Ferguson - Chief Financial Officer Conference Call Participants Ross Osborn - Cantor Fitzgerald Frank Takkinen - Lake Street Capital Markets Operator Greetings. Welcome to the Elutia Q3 2023 Financial Results Call.

Elutia, Inc. (ELUT) Q3 2023 Earnings Call Transcript

- Anticipate 510(k) filing for transformational Drug-Eluting Biomatrix CanGarooRM in Fourth Quarter SILVER SPRING, Md., Nov. 13, 2023 (GLOBE NEWSWIRE) -- Elutia Inc. (Nasdaq: ELUT) (“Elutia”), a company pioneering drug-eluting biomatrix products, today provided a business update and financial results for the third quarter ended September 30, 2023.

Elutia Reports 26% Year-Over-Year Sales Growth of Proprietary Products and Strengthened Balance Sheet in Third Quarter 2023 Financial Results

- Company Now Focused on Proprietary Drug-Eluting Biomatrix Platform - SILVER SPRING, Md., Nov. 09, 2023 (GLOBE NEWSWIRE) -- Elutia Inc. (Nasdaq: ELUT) (“Elutia”), a company pioneering drug-eluting biomatrix products, today announced it completed the divestiture of its Orthobiologics business unit to Berkeley Biologics LLC, a wholly owned subsidiary of GNI Group Ltd.

News for Elutia Inc Stock (ELUT)